View or download posters and publications from 4D pharma plc

Archive:

Date 16 Sep 2021
Title ESMO 2021 - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Document (495KB)
Link
Date 16 Sep 2021
Title ESMO 2021 - Baseline biomarkers associated with clinical benefit in patients with solid tumours refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab
Document (1,024KB)
Link
Date 06 Jul 2021
Title Publication - Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer, Nature Communications
Document
Link visit
Date 25 May 2021
Title DDW 2021 Virtual R&D Event: Phase II clinical trial of Blautix as a treatment for IBS-C and IBS-D
Document (428KB)
Link
Date 24 May 2021
Title DDW 2021 - A Phase II randomized, multi-center study to evaluate the efficacy and safety of the oral single strain Live Biotherapeutic Product (LBP) Blautix in subjects with IBS-C and IBS-D
Document (288KB)
Link
Date 04 May 2021
Title Keystone Symposia, Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics. Engineering live biotherapeutics: approaches, challenges and applications
Document (859KB)
Link
Date 08 Jan 2021
Title Publication - The fecal mycobiome in patients with Irritable Bowel Syndrome, Scientific Reports
Document
Link visit
Date 09 Nov 2020
Title SITC2020, 4D presents first monotherapy data for immuno-oncology LBP MRx0518 in neoadjuvant setting, demonstrating tumor and systemic immune modulation
Document (842KB)
Link
Date 09 Nov 2020
Title SITC2020, 4D presents updated clinical benefit results from Part A of its trial of MRx0518 in combination with pembrolizumab in refractory solid tumors
Document (488KB)
Link
Date 09 Nov 2020
Title SITC2020, trial-in-progress (TiP) poster describing ongoing Part B of its Phase I/II trial of MRx0518 in combination with pembrolizumab in refractory solid tumors
Document (461KB)
Link
Date 07 Jun 2020
Title 4D presents preclinical LBP candidates for neurodegenerative disease and autism at Microbiome Connect Human USA
Document (2,781KB)
Link
Date 29 Apr 2020
Title 4D and OncoDesign present joint AACR poster with additional analysis of MRx0518 activity in pre-clinical model of breast cancer
Document (647KB)
Link
Date 21 Mar 2020
Title Publication - Quality by Design: comparison of design space construction methods in the case of Design of Experiments
Document
Link visit
Date 16 Dec 2019
Title Publication - Differences in the microbiome and metabolome of people with irritable bowel syndrome and bile acid malabsorption
Document
Link visit
Date 06 Dec 2019
Title 4D presents at the Microbiome Movement Gut-Brain-Axis Summit in Boston
Document (2,651KB)
Link
Date 06 Dec 2019
Title 4D presents on the immunology of MRx-4DP0004 in vitro and in a model of severe asthma, at the British Society of Immunology Congress 2019
Document (835KB)
Link
Date 06 Dec 2019
Title 4D presents the preclinical anti-tumour activity and immunology of immuno-oncology LBP MRx0518 at the British Society for Immunology 2019
Document (704KB)
Link
Date 14 Nov 2019
Title 4D presents at the European Microbiome Congress, on LBPs targeting the gut-brain axis
Document (2,410KB)
Link
Date 11 Nov 2019
Title 4D present trial-in-progress poster at SITC 2019, detailing Phase I study of neoadjuvant MRx0518 before surgical resection of solid tumours
Document (587KB)
Link
Date 24 Oct 2019
Title 4D presents pre-clinical data on two candidates for neurodegenerative disease at Neuroscience 2019
Document (789KB)
Link
Date 10 Oct 2019
Title 4D pharma presents on bacterial SCFA metabolites as HDAC inhibitors
Document (783KB)
Link
Date 10 Oct 2019
Title 4D pharma presents additional analysis of Blautix Phase Ib study in IBS
Document (772KB)
Link
Date 10 Oct 2019
Title 4D pharma presents pre-clinical data on two LBP candidates for neurodegenerative disease
Document (673KB)
Link
Date 20 Sep 2019
Title Publication - In vitro Characterization of Gut Microbiota-Derived Bacterial Strains With Neuroprotective Properties
Document
Link visit
Date 09 Sep 2019
Title Publication - Identification performance of MALDI-ToF-MS upon mono- and bi-microbial cultures is cell number and culture proportion dependent
Document
Link visit
Date 25 Jul 2019
Title 4D pharma presents new mechanistic data for oncology programmes
Document (3,248KB)
Link
Date 25 Jul 2019
Title 4D pharma presentation at Oncology Response Summit 2019. Into the Clinic: Challenges & Opportunities
Document (1,294KB)
Link
Date 20 Jun 2019
Title 4D pharma presents at Keystone Symposia:Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, USA
Document (1,475KB)
Link
Date 07 Jun 2019
Title 4D Presents Phase Ib Clinical Data on Thetanix® at ESPGHAN
Document (1,511KB)
Link
Date 03 Jun 2019
Title 4D presents MRx0518 combination study at ASCO 2019, Chicago, USA
Document (581KB)
Link
Date 21 May 2019
Title 4D presents on lead immuno-oncology candidate MRx0518 at 4th Annual Advances in Immuno-Oncology Congress, London, UK
Document (3,895KB)
Link
Date 19 May 2019
Title 4D Presents Phase Ib Clinical Data on Thetanix® at Digestive Disease Week, San Diego
Document (664KB)
Link
Date 13 May 2019
Title 4D announces participation in Neuro4D Conference, Frankfurt, Germany
Document (629KB)
Link
Date 08 Mar 2019
Title 4D announces participation in Chardan’s Inaugural Microbiome Medicines Summit, USA
Document
Link visit
Date 30 Jan 2019
Title 4D pharma presents on MRx0518 at Microbiome Movement - Drug Development Europe, Paris
Document (2,424KB)
Link
Date 29 Jan 2019
Title 4D pharma announces publication of data highlighting immuno-stimulatory properties of MRx0518
Document
Link visit
Date 28 Nov 2018
Title Chardan Microbiome Medicines Landscape Webinar
Document
Link visit
Date 29 Oct 2018
Title 4D pharma present on efficacy of asthma candidate MRx-4DP0004 in a model of severe asthma, Microbiome R&D and Business Collaboration Forum, San Diego, USA
Document (1,058KB)
Link
Date 11 Oct 2018
Title 4D Key Opinion Leader Luncheon: Immuno-oncology
Document (4,087KB)
Link visit
Date 02 Oct 2018
Title 4D present on discovery and development of microbiome-based therapeutics in asthma and immuno-oncology, Microbiome Summit, Vienna, Austria
Document (1,676KB)
Link
Date 16 Sep 2018
Title 4D present on mechanisms of asthma programme MRx0004, EMBO/EMBL Symposia: The Human Microbiome, Heidelberg, Germany
Document (860KB)
Link
Date 14 Aug 2018
Title 4D asthma publication
Document
Link visit
Date 30 Jul 2018
Title Publication - microbiota as HDAC inhibitors
Document
Link visit
Date 27 Jun 2018
Title 4D presents, Live Biotherapeutics: Form Follows Functions, at IHMC 2018
Document (1,593KB)
Link visit
Date 26 Jun 2018
Title 4D present data on IBS microbiome analysis at IHMC Conference, Killarney, Ireland
Document (866KB)
Link
Date 26 Jun 2018
Title 4D present data on gut bacterial strains able to modulate neuroinflammation and neurodegeneration, IHMC Conference, Killarney, Ireland
Document (525KB)
Link
Date 04 Jun 2018
Title 4D Presents Phase Ib Clinical Data on Blautix
Document (457KB)
Link visit
Date 04 Jun 2018
Title Live Biotherapeutics - From Concept to Clinic in Immuno-Oncology
Document (1,987KB)
Link
Date 21 Mar 2018
Title 4D presents data on MRx0518 MoA in immuno-oncology
Document (1,215KB)
Link
Date 12 Feb 2018
Title Live biotherapeutics and immuno-oncology: from discovery to efficacy studies, Cell-Weizmann Institute of Science Symposium: Next Gen Immunology Congress, Rehovot, Isreal
Document (927KB)
Link
Date 05 Feb 2017
Title 4D pharma presents data on asthma programme
Document (643KB)
Link
Date 05 Feb 2017
Title 4D pharma presents data on RA programme
Document (1,452KB)
Link

BACK TO TOP